08:00 , Dec 8, 2008 |  BC Week In Review  |  Company News

InCode management update

InCode BioPharmaceutics Inc. , San Francisco, Calif.   Business: Autoimmune, Cancer, Hematology   Hired: Kevin Stark as president and CEO, formerly executive director at Amgen Inc. and COO at iZumi Bio Inc. ; he replaces...
07:00 , Aug 4, 2008 |  BC Week In Review  |  Clinical News

InCode preclinical data

In primates, rC3-1 delivered directly to the pulmonary artery was well-tolerated and produced no adverse events. Data will be presented at the International Complement Workshop in Basel in September. rC3-1 is a recombinant protein that...
07:00 , Jul 28, 2008 |  BC Week In Review  |  Clinical News

InCode preclinical data

Data from blood samples of patients with PNH showed that rC3-1 prevented the destruction of red blood cells. rC3-1 promotes the enzymatic partial depletion of C3 , which has been shown to reduce cell destruction...
07:00 , Sep 1, 2003 |  BioCentury  |  Strategy

MitoKor: Buy, sell, buy

Lesson: Piecing a company together through M&A can be untidy, and take unexpected directions. Thus it pays to be opportunistic after a deal, as well as before. Shortly after Walter Moos joined MitoKor Inc. as...
08:00 , Jan 14, 2002 |  BioCentury  |  Finance

2002 Financial Markets Preview: Repricing the venture space

Life science venture capital firms raised record money last year, but some later stage companies are having difficulty raising equity because the valuations from their last round - priced in the waning days of the...
07:00 , Jul 2, 2001 |  BC Week In Review  |  Company News

Apollo, MitoKor deal

MitoKor completed its previously announced acquisition of Apollo for stock (see BioCentury, May 14). Apollo Biopharmaceutics Inc., Cambridge, Mass.   MitoKor Inc., San Diego, Calif   Business: Neurological, Metabolic  ...
07:00 , Jul 2, 2001 |  BC Week In Review  |  Company News

BioTime board of directors update

BioTime Inc. (BTX), Berkeley, Calif.   Business: Blood products/substitutes   Appointed: Katherine Gordon, president of Apollo BioPharmaceutics Inc.  ...
07:00 , May 14, 2001 |  BC Week In Review  |  Company News

Apollo, MitoKor deal

In a stock deal, mitochondria company MitoKor will acquire Apollo, which is developing polycyclic phenolic compounds, including estrogenic compounds, for neurological diseases, in a stock deal. Apollo’s ABP-150 is in Phase I trials to treat...
07:00 , May 14, 2001 |  BioCentury  |  Strategy

MitoKor buys into the clinic

Over the last few years, MitoKor Inc. has constructed a platform of technologies geared towards developing drug candidates based on an understanding of the mitochondria. But with preclinical candidates not expected to enter the clinic...
08:00 , Dec 20, 1999 |  BC Week In Review  |  Clinical News

Compounds that bind the vitamin D receptor regulatory update

The University of Kentucky (Lexington, Ky.) received U.S. Patent No. 5,939,407 covering the use of molecules that interact with the vitamin D receptor to prevent neuron loss associated with neurodegenerative conditions. Apollo, which is the...